Duration of correction for human immunodeficiency virus-associated lipoatrophy after retreatment with injectable poly-L-lactic acid.
The Blue Pacific study assessed the effect of injectable poly-L-lactic acid (PLLA) (Sculptra; Dermik Laboratories, a business of Sanofi-Aventis U.S. LLC, Bridgewater, NJ, USA) for the treatment of human immunodeficiency virus (HIV)-associated facial lipoatrophy. This case report describes a patient treated originally with injectable PLLA in the Blue Pacific study, then retreated with injectable PLLA 12 months after completion of his initial treatment sessions. Retreatment was well tolerated and resulted in a correction of facial lipoatrophy for a duration of 2 years 7 months.
Mest
D R
DR
Blue Pacific Aesthetic Medical Group, Inc., 2301 Rosecrans Avenue, Suite 1135, El Segundo, CA 90245, USA. DRMEST@aol.com
Humble
G M
GM
D039682:HIV-Associated Lipodystrophy Syndrome / Q000628:therapy*; D006801:Humans; D007267:Injections; D019344:Lactic Acid / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D011091:Polyesters; D011108:Polymers / Q000008:administration & dosage*; D012074:Remission Induction; D019233:Retreatment; D013997:Time Factors
D011091:Polyesters; D011108:Polymers; D019344:Lactic Acid; C033616:poly(lactide)